Literature DB >> 17012909

Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli.

Zhiyong Zhou1, Charles W Todd, Robert M Wohlhueter, April Price, Lihua Xiao, Paul Schnake, Phillip Cullison Bonner, Amy M Martin, Ira F Goldman, Patricia De La Vega, Venkatachalam Udhayakumar, Altaf A Lal.   

Abstract

A synthetic multistage, multi-epitope Plasmodium falciparum malaria antigen (FALVAC-1A) was designed and evaluated in silico, and then the gene was constructed and expressed in Escherichia coli. The FALVAC-1A protein was purified by inclusion body isolation, followed by affinity and ion exchange chromatography. Although FALVAC-1A was a synthetic antigen, it folded to a specific, but as yet incompletely defined, molecular conformation that was stable and comparable from lot to lot. When formulated with four different adjuvants, FALVAC-1A was highly immunogenic in rabbits, inducing not only ELISA reactivity to the cognate antigen and most of its component epitopes, but also in vitro activity against P. falciparum parasites as demonstrated by inhibition of sporozoite invasion, antibody dependent cellular inhibition and the immunofluorescence assay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17012909     DOI: 10.4161/hv.2.1.2437

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  6 in total

1.  Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.

Authors:  Masanori Mizutani; Mitsuhiro Iyori; Andrew M Blagborough; Shinya Fukumoto; Tomohiro Funatsu; Robert E Sinden; Shigeto Yoshida
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

2.  Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.

Authors:  S A Kaba; A Price; Z Zhou; V Sundaram; P Schnake; I F Goldman; A A Lal; V Udhayakumar; C W Todd
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

Review 3.  Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

Authors:  S L Takala; C V Plowe
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

4.  Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.

Authors:  Luciana M Silva-Flannery; Monica Cabrera-Mora; Jianlin Jiang; Alberto Moreno
Journal:  Microbes Infect       Date:  2008-10-26       Impact factor: 2.700

5.  Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail Challenge.

Authors:  Alexander Boes; Holger Spiegel; Nadja Voepel; Gueven Edgue; Veronique Beiss; Stephanie Kapelski; Rolf Fendel; Matthias Scheuermayer; Gabriele Pradel; Judith M Bolscher; Marije C Behet; Koen J Dechering; Cornelus C Hermsen; Robert W Sauerwein; Stefan Schillberg; Andreas Reimann; Rainer Fischer
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Codon optimization with deep learning to enhance protein expression.

Authors:  Hongguang Fu; Yanbing Liang; Xiuqin Zhong; ZhiLing Pan; Lei Huang; HaiLin Zhang; Yang Xu; Wei Zhou; Zhong Liu
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.